Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BioLineRx Ltd
BLRX | US
2.39
USD0.01
0.42%
BLRX | US
About BioLineRx Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
2.39
Open
2.36
High
2.51
Low
2.35
BioLineRx Ltd. a pre-commercial-stage biopharmaceutical company focuses on oncology. The company develops Motixafortide a peptide which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134 an immuno-oncology agent which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010 a customized proprietary pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in Israel.
View LessBLRX | US
Risk
59.4
Sharpe
-0.30
Luna's Score
45/100
Recommendation
Sell
Luna says (BLRX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
16.9%1 month
59.4%3 months
46.3%6 months
47.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.64
Debt to equity
2.24
Debt to assets
0.48
Ent. to EBITDA
-0.67
Ent. to rev.
1.86
PEG
0.20
Other Fundamentals
EBITDA
-33.08M
MarketCap
209.67M
MarketCap(USD)
209.67M
Div. yield
-
Op. margin
-107.05
Erngs. growth
-
Rev. growth
-
Ret. on equity
-171.94
Short ratio
0.93
Short perc.
0.17
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.33
Range1M
0.60
Range3M
1.04
Volumes: Market Activity
Rel. volume
0.31
Price X volume
12.53K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.67 | - | Cheaper |
| Ent. to Revenue | 1.86 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.64 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 46.28 | - | Lower Risk |
| Debt to Equity | 2.24 | -1.23 | Expensive |
| Debt to Assets | 0.48 | 0.25 | Expensive |
| Market Cap | 209.67M | - | Emerging |
